DOP2011000378A - Nuevo compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias - Google Patents

Nuevo compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias

Info

Publication number
DOP2011000378A
DOP2011000378A DO2011000378A DO2011000378A DOP2011000378A DO P2011000378 A DOP2011000378 A DO P2011000378A DO 2011000378 A DO2011000378 A DO 2011000378A DO 2011000378 A DO2011000378 A DO 2011000378A DO P2011000378 A DOP2011000378 A DO P2011000378A
Authority
DO
Dominican Republic
Prior art keywords
degenerative
treatment
inflammatory diseases
useful compound
new useful
Prior art date
Application number
DO2011000378A
Other languages
English (en)
Inventor
Javier Blanc
Christel Jeanne Marie Menet
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of DOP2011000378A publication Critical patent/DOP2011000378A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DO2011000378A 2009-06-26 2011-12-06 Nuevo compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias DOP2011000378A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25

Publications (1)

Publication Number Publication Date
DOP2011000378A true DOP2011000378A (es) 2012-02-15

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000378A DOP2011000378A (es) 2009-06-26 2011-12-06 Nuevo compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias

Country Status (38)

Country Link
US (2) US8796457B2 (es)
EP (2) EP2445912B1 (es)
JP (1) JP5486084B2 (es)
KR (1) KR101712561B1 (es)
CN (1) CN102459261B (es)
AR (1) AR077221A1 (es)
AU (1) AU2010264635B2 (es)
BR (1) BRPI1014759A2 (es)
CA (1) CA2765988C (es)
CL (1) CL2011003276A1 (es)
CO (1) CO6491039A2 (es)
CR (1) CR20110673A (es)
CY (1) CY1119711T1 (es)
DK (2) DK2445912T3 (es)
DO (1) DOP2011000378A (es)
EA (1) EA020111B1 (es)
ES (2) ES2634325T3 (es)
HK (2) HK1168098A1 (es)
HR (2) HRP20141057T1 (es)
HU (1) HUE034205T2 (es)
IL (1) IL216618A (es)
JO (1) JO3030B1 (es)
LT (1) LT2792677T (es)
MA (1) MA33447B1 (es)
ME (1) ME01916B (es)
MX (1) MX2011013451A (es)
NZ (1) NZ596836A (es)
PE (1) PE20120494A1 (es)
PL (2) PL2792677T3 (es)
PT (2) PT2445912E (es)
RS (1) RS53617B1 (es)
SG (1) SG177359A1 (es)
SI (2) SI2445912T1 (es)
SM (1) SMT201400169B (es)
TW (1) TWI469981B (es)
UY (1) UY32741A (es)
WO (1) WO2010149771A1 (es)
ZA (1) ZA201109502B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2696869B1 (en) * 2011-04-12 2017-08-23 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
KR20200039028A (ko) * 2011-10-11 2020-04-14 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
MA37775A1 (fr) * 2012-06-22 2017-04-28 Galapagos Nv Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées
CA2922770A1 (en) 2013-09-05 2015-03-12 F. Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
KR20170134751A (ko) * 2015-04-13 2017-12-06 갈라파고스 엔.브이. 심혈관 질환의 치료 방법
KR102492378B1 (ko) 2016-07-26 2023-01-27 톈진 롱보진 파마시우티컬 씨오., 엘티디. 선택적 jak 저해제로서 화합물, 및 이의 염 및 치료학적 용도
US11427581B2 (en) 2018-01-31 2022-08-30 Zhuhai United Laboratories Co., Ltd. JAK inhibitor and use thereof
CA3110891A1 (en) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
CA3128212A1 (en) 2019-01-31 2020-08-06 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
KR20230012501A (ko) 2020-05-19 2023-01-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500854B1 (en) 1999-01-29 2002-12-31 Chugai Sei Yaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
AU2003231880A1 (en) * 2002-05-30 2003-12-19 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
JP2006517580A (ja) 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
ES2549862T3 (es) * 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
AU2008277628B2 (en) 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
AU2010254806C1 (en) 2009-06-05 2016-07-07 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Also Published As

Publication number Publication date
LT2792677T (lt) 2017-07-25
HK1202537A1 (en) 2015-10-02
PT2792677T (pt) 2017-07-06
SMT201400169B (it) 2015-01-15
ZA201109502B (en) 2012-09-26
EP2445912A1 (en) 2012-05-02
BRPI1014759A2 (pt) 2016-04-19
CA2765988A1 (en) 2010-12-29
IL216618A0 (en) 2012-02-29
SI2445912T1 (sl) 2014-12-31
CL2011003276A1 (es) 2012-08-31
PE20120494A1 (es) 2012-05-17
US8796457B2 (en) 2014-08-05
PT2445912E (pt) 2014-11-07
EP2792677A1 (en) 2014-10-22
ES2519170T3 (es) 2014-11-06
EA201270076A1 (ru) 2012-08-30
SG177359A1 (en) 2012-02-28
MA33447B1 (fr) 2012-07-03
AU2010264635B2 (en) 2015-05-07
NZ596836A (en) 2013-02-22
US20150031671A1 (en) 2015-01-29
JP5486084B2 (ja) 2014-05-07
AU2010264635A1 (en) 2011-12-22
AR077221A1 (es) 2011-08-10
PL2445912T3 (pl) 2015-02-27
UY32741A (es) 2011-01-31
IL216618A (en) 2014-09-30
CO6491039A2 (es) 2012-07-31
DK2445912T3 (da) 2014-11-10
US20100331359A1 (en) 2010-12-30
JP2012530767A (ja) 2012-12-06
HRP20171024T1 (hr) 2017-10-06
SI2792677T1 (sl) 2017-08-31
US9505754B2 (en) 2016-11-29
CY1119711T1 (el) 2018-06-27
HK1168098A1 (en) 2012-12-21
PL2792677T3 (pl) 2017-09-29
EP2445912B1 (en) 2014-08-13
CN102459261A (zh) 2012-05-16
ES2634325T3 (es) 2017-09-27
TWI469981B (zh) 2015-01-21
ME01916B (me) 2015-05-20
MX2011013451A (es) 2012-04-30
TW201103937A (en) 2011-02-01
DK2792677T3 (en) 2017-07-10
EA020111B1 (ru) 2014-08-29
KR20120059487A (ko) 2012-06-08
RS53617B1 (en) 2015-04-30
JO3030B1 (ar) 2016-09-05
HRP20141057T1 (en) 2015-03-13
HUE034205T2 (en) 2018-01-29
EP2792677B1 (en) 2017-04-26
KR101712561B1 (ko) 2017-03-06
CN102459261B (zh) 2014-11-05
CR20110673A (es) 2012-02-09
WO2010149771A1 (en) 2010-12-29
CA2765988C (en) 2017-08-29

Similar Documents

Publication Publication Date Title
DOP2011000378A (es) Nuevo compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
HK1195311A1 (zh) 用於治療變性疾病和炎性疾病的新化合物
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI1011587A2 (pt) compostos e composições terapèuticas
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
CO6880069A2 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BRPI1014528A2 (pt) compostos para tratamento de inflamação e dor
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase
BRPI0912412A2 (pt) compostos de pirazina fundidos úteis para o tratamento de doenças degenerativas e inflamatórias.
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia
BR112012004258A2 (pt) "método com tetraarilborato para fabricação de bifenilos substituintes"
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
BR112014011898A2 (pt) métodos e composições para o tratamento de diabetes e sintomas relacionados
BRPI0822292A2 (pt) Fármaco-alvo eficaz para o tratamento de tuberculose